Therefore, either TFEB expression, or TRPML1/2 activation in conjunction with iron chelation, may be promising therapeutic approaches toward treating neurodegenerative diseases associated with iron dyshomeostasis. This evidence concerns the gene MCOLN1 and neurodegenerative disease.